# NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer

> **NCT03734809** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 43 (actual)

## Conditions studied

- NPC

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03734809
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-03
- **Primary completion:** 2025-01-25
- **Final completion:** 2027-12-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03734809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03734809, "NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03734809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*